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Introduction {#sec1}
============

As the first line of host defense, innate immunity is activated by a non-clonal system of receptors ([@bib22]). These receptors sense microbial molecules and subsequently trigger specific signaling pathways that regulate target genes. The virtue of the system lies in the distinctive connection between individual microbes and the activation of certain sets of target host immune genes. Thus, each pathogen is associated with a specific transcriptional outcome in host defense ([@bib22]).

In *Drosophila*, there is differential transcriptional activation by nuclear factor κB (NF-κB) pathways, depending on the bacterial type ([@bib19], [@bib9]). This has been attributed to the ability of the upstream host receptors, peptidoglycan recognition proteins (PGRPs), to discriminate between different structures of bacterial peptidoglycan (PG) (for review, see [@bib29]). PGRPs are highly conserved from insects to mammals and show distinct specificities in PG recognition. These specificities are thought to be the main determinant of the downstream response outcome.

Polymeric PG is composed of repeating units of muropeptide, comprising disaccharide *N-*acetyl glucosaminyl (GlcNAc)-*N-*acetylmuramic acid (MurNAC) linked to a stem peptide of [d]{.smallcaps}- or [l]{.smallcaps}- (or *meso-*) amino acids, in which the third amino acid is lysine (Lys) in Gram-positive bacteria and diaminopimelic acid (DAP) in Gram-negative bacteria and in certain Gram-positive bacilli. Circulating PGRP-SA is thought to interact preferentially with Lys-type PG and thus activate the Toll pathway ([@bib21]). In contrast, the cell membrane-associated PGRP-LC and intracellular PGRP-LE have been identified as the immunodeficiency (IMD) cascade receptors sensing DAP-type PG ([@bib21], [@bib16], [@bib36]). Activation of these pathways culminates in the NF-κB-dependent differential induction of antimicrobial peptide (AMP) genes (reviewed in [@bib18]). This differential induction is thought to be the consequence of upstream structural discrimination in PG recognition.

This view of Lys versus DAP PG discrimination has been based on the following evidence.1.Interaction assays of recombinant PGRP-SA with purified PG have shown binding to both Lys- and DAP-type Gram-negative PG, but not to amidated DAP-type found in Gram-positive bacilli such as *Bacillus subtilis* and *B. thuringiensis* ([@bib4], [@bib23], [@bib20]). In all of these experiments, however, PG was not quantified in terms of the number of sugar molecules added to the reaction, but only in terms of equal weight, precluding any insight into potentially real differences of PGRP-SA binding to different types of PG. Moreover, these assays were performed either using a 20-mM Tris-HCl, pH 7.8, 300-mM NaCl buffer ([@bib4], [@bib20]) or a 20-mM HEPES, pH 7.2, 150-mM NaCl buffer ([@bib23]). Therefore, the binding conditions were not similar to what may happen in the hemolymph (insect equivalent of mammalian blood), in which all of these interactions take place. PG binding assays of PGRP-LE (albeit with the same experimental drawbacks outlined above) also suggested a clear binding preference for DAP-type PG ([@bib36]). In a notable exception, however, [@bib23] have observed the binding of PGRP-LCx (the PGRP-LC isoform with PG binding ability) to polymeric Lys-type PG *in vitro.*2.Structural studies have sought to corroborate the suggested Lys/DAP structural discrimination by comparing and contrasting the unligated structure of PGRP-SA ([@bib4], [@bib28]), with the structure of PGRP-LC co-crystallized with a naturally occurring DAP-type PG fragment from *Bordetella pertusis*, known as tracheal cytotoxin (TCT; [@bib5]). TCT, which is essentially monomeric PG (GlcNAc-1,6-anhydro-MurNAc-[l]{.smallcaps}-Ala-γ-[d]{.smallcaps}-Glu-*meso-*DAP-[d]{.smallcaps}-Ala), strongly activates IMD through PGRP-LC ([@bib16]). In the PGRP-LC/TCT structure, Arg^413^, Asp^395^, and Trp^394^ of PGRP-LCx form a binding pocket for the DAP group. Since this pocket is surrounded by three solvent-exposed basic residues (Arg^349^, Lys^423^, and Arg^427^), the authors of the report argue that the presence of an Lys instead of a DAP would destabilize the docking interaction. Moreover, the absence of positively charged residues in the same region of PGRP-SA would be consistent with preferred binding to Lys-type PG ([@bib5]). However, evidence from a crystal structure will always provide a "freeze-frame," and therefore these assertions may prove problematic when considering the whole "movie." For example, one could argue that the positive charge potential of the three solvent-exposed residues mentioned above is sufficiently flexible and distant (\>10 Å) from any ligand that it would not interfere with binding to Lys. Moreover, their surface positive charge potential may be fulfilled with water (see [Results](#sec2){ref-type="sec"} for a more comprehensive appraisal of alternative options).

It is also not clear how widespread the recognition of monomeric PG fragments is, as opposed to polymeric ones. If the latter is also a binding possibility, then the amino group linked to the epsilon carbon of the Lys residue in polymeric Lys-type PG will not retain a basic charge if there is a cross-bridge linking it to [d]{.smallcaps}-Ala and consequently connecting two different PG stem peptides. Thus, as has been shown by [@bib23], this will lead to PGRP-LCx binding to Lys-type PG. The hypothetical binding of PGRP-SA to monomeric PG is also problematic, as it has been shown that PGRP-SA from the large beetle *Tenebrio molitor* activates downstream signaling through clustering to polymeric Lys-type PG ([@bib26]). In addition, monomeric muropeptides fail to activate Toll ([@bib11]), while muramidase-treated PG is unable to induce either pathway ([@bib21], [@bib11]). Therefore, comparing the PGRP-LC/TCT structure with a hypothetical entity of PGRP-SA/Lys-type monomer may not be physiologically relevant. Structural studies using analogs of monomeric PG (muramyl pentapeptides; see [@bib13], [@bib35]) and PGRP-LC may have limited *in vivo* relevance due to the differences between the synthetic muropeptides that were used and the native ones.

Moreover, in *Tenebrio molitor*, polymeric DAP-type PG from *Bacillus subtilis* and *Escherichia coli* was bound by PGRP-SA, leading to activation of the proteolytic cascade upstream of Toll as Lys-type PG did ([@bib40]). This indicated that any structural discrimination was certainly not an insect-wide phenomenon.3.*In vivo* studies have also indicated that the injection of Lys-type PG activates Toll at least 3× more than DAP-type PG ([@bib21]). Again, the lack of quantification by the number of sugars injected (and not by weight, which was typically 50 mg/mL) precludes a direct comparison.

Our previous work has established that accessibility to PG played an important role in PGRP-SA recognition of whole Gram-positive bacteria with Lys-type PG. Wall teichoic acids (WTAs) are anionic polymers of glycerol- or ribitol-phosphate that conceal the PG layer from direct interaction with the extracellular environment. Removal of WTAs from *Staphylococcus aureus* (*S. aureusΔtagO*), increased PGRP-SA binding to whole bacteria by 1,000× and made the PGRP-SA-dependent clearance of *S. aureus* independent of Toll ([@bib2]).

In this study, we address the importance of accessibility to PG in PGRP-mediated recognition of whole bacteria in more general terms. In addition to *S. aureus* as the Lys-type representative, we used *B. subtilis* as the DAP-type model. We found that in a hemolymph-like buffer, both PGRPs were able to bind *in vitro* both bacteria with exposed PGs at their surface, as well as their purified and quantified PG. When WTAs were removed, PGRP-SA was able to bind significantly more both types of bacteria, while PGRP-LC was able to bind significantly more only to *B. subtilis* and at the margin of statistical significance to *S. aureus*. In addition, there was no measurable preference of PGRP-SA binding to any of the two PGs *in vitro*, while PGRP-LC showed a quantifiable 5× preference for DAP-type PG. Despite that, PGRP-LC co-localized with the cell surface of both *S. aureus* and *S. aureusΔTagO ex vivo* and activated a robust antimicrobial response that was statistically comparable to that mediated by PGRP-SA. Following infection with *S. aureus* or *B. subtilis*, differential AMP induction was observed. However, when WTAs were removed, antimicrobial responses per bacterial number became statistically indistinguishable across the course of infection, indicating that more accessibility to PG equalized downstream transcription. At the level of the whole organism, flies that were double mutant for PGRP-SA and PGRP-LC were more susceptible than single mutants to infection with WTA-less bacteria, while the growth of WTA-less bacteria showed a statistically significant increase in double mutant flies compared to the single fly mutants.

We argue that accessibility to PG is one of the main determinants of PGRP specificity in *Drosophila*. Given the evolutionary conservation of innate immunity in most metazoans, our results have implications for animals when PGRPs are used as recognition receptors of whole bacteria.

Results {#sec2}
=======

We chose to use two bacteria (*S. aureus* and *B. subtilis*) that carry PGs that represent a wide range of bacteria and bacilli. In general, bacterial PG can be divided into two groups: group A (in which crosslinking between stem peptides occurs between positions 3 and 4), which is the most common among pathogenic bacteria ([@bib30]), and group B (in which crosslinking between stem peptides occurs between positions 2 and 4), found only among some coryneform bacteria, especially from plants ([@bib30]). *S. aureus* PG belongs to group A3 (i.e., crosslinking between stem peptides is made up of interpeptide bridges consisting of monocarboxylic [l]{.smallcaps}-amino acids or glycine or both). PG of the A3 group is very common among Gram-positive bacteria ([@bib30]). *B. subtilis* PG belongs to group A1 (i.e., different stem peptides are connected through direct crosslinking). PG of the A1 group is very common among Gram-negative bacteria.

Previous studies (e.g., [@bib19], [@bib21], [@bib4]) have used the Gram-positive bacterium *Micrococcus luteus* as "the Gram-positive bacterium of choice" for infection studies, and subsequently many labs used *M. luteus* PG for interaction studies. However, *M. luteus* PG belongs to group A2 (in which crosslinking is made by one polymerized stem peptide), which is not frequently found among bacteria ([@bib30]). The PGs that belong to this group have two important particularities: \>50% of the *N*-acetylmuramic residues are not substituted by a stem peptide; all glycine residues in the native cell wall are C-terminal and therefore are not involved in the crosslinking between different stem peptides ([@bib30]). These characteristics make *M. luteus* PG not a representative choice for a Gram-positive bacterium. Moreover, *M. luteus* genetics is not at all developed, while both *S. aureus* and *B. subtilis* have been used as genetic models and thus we know a great deal about their cell wall physiology. This is an important point since only the use of bacterial genetics will reveal if and how Gram-positive bacteria and bacilli that have their PG directly exposed to the host conceal it from PGRPs.

Removal of WTAs Enhances Binding of PGRP-SA and PGRP-LC to Whole Bacteria {#sec2.1}
-------------------------------------------------------------------------

We hypothesized that differential activation of immunity by different bacterial species may not be due to the structural discrimination of PG, but instead is due to differential PG accessibility. To test this hypothesis, we compared the *in vitro* binding of fluorescently tagged PGRP subtypes to whole bacteria in a buffer similar to hemolymph ([@bib7]; [@bib37]; henceforth called HemoBuffer; see [Method Details](#sec4.4){ref-type="sec"} for recipe). Binding to the parental reference strains (National Collection of Type Cultures \[NCTC\] 8325-4 for *S. aureus* and EB6 for *B. subtilis*) was used as a control. Our results are shown in [Figure 1](#fig1){ref-type="fig"} for PGRP-SA and [Figure 2](#fig2){ref-type="fig"} for PGRP-LC, while quantification of these bindings is shown in [Figure S1](#mmc1){ref-type="supplementary-material"}. To compare binding of mCherry-PGRP-SA and mCherry-PGRP-LC to different bacterial strains, we used a 10-ms exposure time. Given the variability in signal intensity, for visualization purposes only, the contrast of images shown in [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} was adjusted for easier visual comparison of images with high signal intensities, while the contrast in [Figures S2](#mmc1){ref-type="supplementary-material"}A (PGRP-SA) and [S2](#mmc1){ref-type="supplementary-material"}B (PGRP-LC) was adjusted for easier visual comparison of images with low signal intensities. Statistical tests for all of the possible comparisons are presented in [Table S1](#mmc1){ref-type="supplementary-material"}.Figure 1Binding of PGRP-SA to a Gram-Positive Bacterium and a Gram-positive Bacillus *In Vitro*Binding of a fluorescently tagged PGRP-SA (mCherry_PGRP-SA) in (A) phase contrast channel, (B) mCherry channel, and (C) overlay. We tested for binding to *S. aureus* (Ai--Ci), *S. aureusTagO* (Aii--Cii), *B. subtilis* (Aiii--Ciii), and *B. subtilisTagO* (Aiv--Civ). Increased binding was consistently observed in the TagO mutants compared to their parental strains. See main text and [Figure S1](#mmc1){ref-type="supplementary-material"} for the quantification of median intensity binding.Figure 2Binding of PGRP-LC to a Gram-Positive Bacterium and a Gram-Positive Bacillus *In Vitro*Binding of a fluorescently tagged PGRP-LC (mCherry_PGRP-LC) in (A) phase contrast channel, (B) mCherry channel, and (C) overlay. We tested for binding to *S. aureus* (Ai--Ci), *S. aureusTagO* (Aii--Cii), *B. subtilis* (Aiii--Ciii), and *B. subtilisTagO* (Aiv--Civ). Increased binding was consistently observed in the TagO mutants compared to their parental strains. See main text and [Figure S1](#mmc1){ref-type="supplementary-material"} for the quantification of median intensity binding.

PGRP-SA demonstrated no statistical difference between *S. aureus* NCTC and *B. subtilis* EB6 binding ([Figures 1](#fig1){ref-type="fig"}Ai--1Ci,1Aiii--1Ciii, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B; [Table S1](#mmc1){ref-type="supplementary-material"}). The median intensity of the fluorescent signal of mCherry-PGRP-SA associated with bacteria was 16 and 23, respectively. Similarly, we found no significant difference between mCherry-PGRP-LC binding to *S. aureus* NCTC and *B. subtilis* EB6 ([Figures 2](#fig2){ref-type="fig"}Ai--2Ci, 2Aiii--2Ciii, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D; [Table S1](#mmc1){ref-type="supplementary-material"}). The median intensity of the fluorescent signal of mCherry-PGRP-LC associated with bacteria was 13 and 64, respectively. Upon WTA removal, both PGRPs displayed increased recognition of both bacteria (see [Figures 1](#fig1){ref-type="fig"}Aii--1Cii and 1Aiv--1Civ for PGRP-SA and [2Aii--2Cii and 2Aiv--2](#fig2){ref-type="fig"}Civ for PGRP-LC). Quantification showed that PGRP-SA binding was significantly increased in both *S. aureusΔTagO* (with a median fluorescent signal increase from 16 to 379) and *B. subtilisΔTagO* (with a median fluorescent signal increase from 23 to 1,593) ([Figure S1](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}).

However, it was crucial to verify that the increased PGRP binding to the *ΔTagO* mutants was not a result of the mCherry protein tag. To this end, we constructed and purified mutant versions of mCherry-PGRP-SA that carried either or both of the mutations C48 to Y and C54 to Y ([Figure S3](#mmc1){ref-type="supplementary-material"}). A C54-to-Y change is the mutation present in *Drosophila PGRP-SA*^*seml*^ flies, which disrupts the highly conserved disulfide bridge formed between Cys48 and Cys54 ([@bib24]). This bond tethers the H2 helix to the central β sheet through the L1 loop ([@bib4]), and its disruption abrogates downstream signaling ([@bib24]). In addition, to prevent the formation of alternative inter-disulfide bridges, we introduced the mutation C48 to Y. We reckoned that a C-to-Y rather than a C-to-A change would alleviate problems in expression of the C48A mutant observed previously ([@bib4]). The expression of the recombinant m-Cherry and mCherry_PGRP-SA is shown in [Figure S3](#mmc1){ref-type="supplementary-material"}A, while the expression of mCherry_PGRP-SA^C48YC54Y^ protein and the single mCherry_PGRP-SA^C48Y^ and mCherry_PGRP-SA^C54Y^ mutants is shown in [Figure S3](#mmc1){ref-type="supplementary-material"}B. The single mutants showed a high number of multimer forms; however, the double mutant showed protein expression similar to that of the wild-type protein ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Despite its normal expression, mCherry_PGRP-SA^C48YC54Y^ was not able to bind the PG of either bacterium ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Consistent with this, the mutant mCherry_PGRP-SA^C48YC54Y^ was unable to bind to *S. aureus* NCTC and *S. aureusΔTagO* ([Figure S4](#mmc1){ref-type="supplementary-material"}A) and to *B. subtilis* and *B. subtilisΔTagO* ([Figure S4](#mmc1){ref-type="supplementary-material"}B). The results in [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"} clearly show that only the PGRP-SA part of the mCherry_PGRP-SA fusion was responsible for binding.

PGRP-LC binding to *B. subtilisΔTagO* was also significantly intensified compared to the parental strain with a median fluorescent signal that increased from 64 to 13,402 ([Figures 2](#fig2){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}D; [Table S1](#mmc1){ref-type="supplementary-material"}). Binding of PGRP-LC to *S. aureusΔTagO* was also increased from 13 to 88, but statistically it was just below a significant p value ([Figure S1](#mmc1){ref-type="supplementary-material"}D; [Table S1](#mmc1){ref-type="supplementary-material"}). Nevertheless, a closer look at the binding values of PGRP-LC to *S. aureusΔTagO* ([Figure S1](#mmc1){ref-type="supplementary-material"}C) showed that most were above the *S. aureus* NCTC parental strain. Consistent with this, using a longer exposure time (500 ms) to visualize the fluorescent protein bound to the bacterial surface, PGRP-LC binding to *S. aureusΔTagO* was significantly increased (with a median fluorescent signal from 175.5 to 5,437; data not shown).

These results indicated that PGRP-SA showed no apparent discrimination between the two wild-type strains of bacteria. However, when WTAs were removed, PGRP-SA had a preference for *B. subtilisΔTagO*. PGRP-LC showed no discrimination between the wild-type parental strains. When WTAs were removed, *B. subtilisΔTagO* was the preferred strain of PGRP-LC, while binding to *S. aureus* increased but not as much. Nevertheless, the latter result was contrary to expectations, as PGRP-LC was not supposed to bind Gram-positive bacteria. Therefore, we wanted to explore the interaction of live *S. aureus* bacteria with primary macrophages expressing PGRP-LC on their membrane.

This was because our *in vitro* binding experiments used an mCherry-PGRP-LC construct that only included the PGRP ectodomain of the protein, so we wanted to ascertain that when expressed in *Drosophila* cells, transmembrane PGRP-LC was also able to bind to *S. aureus* and *B. subtilis* wild-type strains and their WTA-less mutants. To this end, we used a *UAS-PGRP-LCx-GFP* transgene ([@bib31]) expressed in post-embryonic hemocytes through the *hemolectin-GAL4* driver. To visualize binding, we devised an *ex vivo* system of hemocyte imaging (see [Method Details](#sec4.4){ref-type="sec"}). Briefly, we bled *hml-GAL4; UAS-PGRP-LCx-GFP* larvae on a slide to isolate hemocytes, which were then kept in a humid chamber to preserve them for live imaging. Bacteria were stained with DAPI before being added to the hemocyte preparation. The results are shown in [Figure 3](#fig3){ref-type="fig"}.Figure 3Binding of PGRP-LC to a Gram-Positive Bacterium and a Gram-Positive Bacillus *Ex Vivo*The GFP-tagged transmembrane PGRP-LCx (GFP-PGRP-LCx, expressed in macrophages) was assessed by fluorescence imaging for binding to *S. aureus* (Ai--Ei), *S. aureusTagO* (Aii--Eii), *B. subtilis* (Aiii--Eiii), and *B. subtilisTagO* (Aiv--Eiv), respectively. (Ai--Aiv) GFP-PGRP-LCx-expressing hemocytes were mixed with bacteria. (Bi--Biv) Bacteria were pre-stained and identified by DAPI. (Ci)--(Civ) presents corresponding DIC images in which the extent of macrophages is indicated by the dashed outlines. (Di--Div) Dashed squared regions (82 μm) indicated in (A)--(C) are shown as a dual color overlay of GFP (PGRP-LC) and DAPI (bacteria) signals. (Ei--Eiv) Plots of fluorescence intensity along the dashed lines in (Di--Div) (15 μm transect) are shown highlighting the overlap of the extracellular signals between GFP and DAPI.

[@bib31] have described the pathogen-induced detachment of a FLAG-tagged PGRP-LCx from the membrane of S2 cells upon infection with *E. coli* or *Salmonella typhimurium* (Gram negative), which did not happen following challenge with heat-killed Gram-negative bacteria or live *Staphylococcus carnosus* (Gram positive). We also observed that the fluorescent signal of the GFP linked to the extracellular domain of PGRP-LCx detached from the cell membrane and co-localized with bacteria away from the cell surface and in the extracellular space. However, this was observed both after challenge with live *S. aureus* ([Figures 3](#fig3){ref-type="fig"}Ai--3Di; [Video S1](#mmc2){ref-type="supplementary-material"} up to 0 min:10 s) and live *S. aureusΔTagO* ([Figures 3](#fig3){ref-type="fig"}Aii--3Dii; [Video S1](#mmc2){ref-type="supplementary-material"}, 0 min:11 s--0 min:20 s). As expected, PGRP-LCx also interacted with *B. subtilis* and *B. subitilisΔTagO* ([Figures 3](#fig3){ref-type="fig"}Aiii--3Diii and 3Aiv--3Div; data not shown).

Video S1. *Ex Vivo* Interaction between Primary Larval Macrophages Expressing Full-Length GFP-PGRP-LCx with *S. aureus* Bacteria, Related to Figure 3*S. aureus* (up to 0mins:10secs) and *S. aureusΔTagO* (0mins:11secs-0mins:20secs).

Therefore, in keeping with our *in vitro* results as presented in [Figures 2](#fig2){ref-type="fig"}, [S1](#mmc1){ref-type="supplementary-material"}, and [S2](#mmc1){ref-type="supplementary-material"}, our imaging results with *hml-GAL4; UAS-PGRP-LCx-GFP* larval hemocytes indicated abundant interactions of cleaved PGRP-LCx at the level of the bacterial surface with both wild-type and WTA-less bacterial strains, irrespective of PG type. Moreover, this indicated that the use of only the PGRP-LC ectodomain was a meaningful way to test the binding of the receptor to PG, as (at the cellular level) it showed the same engagement with bacteria as the full-length protein.

PGRP-SA Binds Similarly to Purified and Quantified Polymeric Lys-Type and DAP-Type PG, whereas PGRP-LC Binds More to DAP-Type PG {#sec2.2}
--------------------------------------------------------------------------------------------------------------------------------

To circumvent the caveats of previous studies ([@bib4], [@bib23], [@bib20]), we conducted binding experiments using HemoBuffer and quantified pure polymeric PG from *S. aureus* and *B. subtilis*. Briefly (see the full protocol in [Method Details](#sec4.4){ref-type="sec"}), PG was hydrolyzed to glucosamine and muramic acid (controlling for the efficient removal of *N*-acetyl groups without affecting the sugar molecules and avoiding any WTA contamination) and chromatographically separated. The areas of chromatogram peaks were quantified in comparison to controls in which the concentration of glucosamine and muramic acid were known. With this method, we were able to determine exactly the amount of glucosamine and muramic acid used in our binding assays and therefore used precisely quantified PG. In turn, this helped in the use of PG suspensions with the same concentration of MurNAc in the binding reactions.

Our results indicated that contrary to previous observations ([@bib4], [@bib20]), given the appropriate buffer, PGRP-SA was able to bind *B. subtilis* PG ([Figure 4](#fig4){ref-type="fig"}A). PGRP-LC was able to bind more to *S. aureus* PG in PBS or HemoBuffer than in Tris-NaCl ([Figure 4](#fig4){ref-type="fig"}B). In this context, binding of the two PGRPs to the Lys-type PG of *S. aureus* was statistically indistinguishable ([Figure 4](#fig4){ref-type="fig"}B). Binding of the two PGRPs to *B. subtilis* PG (DAP type) showed a statistically significant difference with PGRP-SA/PG co-immunoprecipitation intensity at 4 × 10^6^ U, while PGRP-LC/PG co-immunoprecipitation intensity was at 6 × 10^6^ U ([Figure 4](#fig4){ref-type="fig"}C). This indicated that PGRP-LC bound more to *B. subtilis* PG than to *S. aureus* PG, as previously proposed ([@bib21], [@bib16], [@bib11], [@bib13], [@bib2]). Nevertheless, we observed no statistical difference in the binding of each PGRP when comparing parental versus *ΔTagO* PG ([Figure 4](#fig4){ref-type="fig"}C). This indicated that the increase in binding of whole bacteria that we have identified with the removal of WTAs was not the result of a change in PG itself, but a consequence of increased accessibility. In this context, we note that the high-performance liquid chromatography (HPLC) profiles of PGs from parental and *ΔTagO* strains were identical ([Figure S5](#mmc1){ref-type="supplementary-material"}A for *B. subtilis*; see [@bib1] for *S. aureus*).Figure 4Binding of PGRP-SA and PGRP-LC to Purified and Quantified Peptidoglycan(A) PGRP-SA was able to bind to DAP-type PG in PBS and HemoBuffer.(B) Binding of PGRP-LC to the same type of PG was statistically higher, indicating a preference for DAP-type PG.(C) In contrast, binding of the two PGRPs to *S. aureus* PG was statistically indistinguishable (when comparing binding assays in HemoBuffer). This was not the case in saturation experiments, however as seen in [Figure S5](#mmc1){ref-type="supplementary-material"}. Binding of the two PGRPs to TagO versus parental strain PG was statistically indistinguishable, indicating that the PG itself did not change when WTAs were removed.PG quantified as in [Method Details](#sec4.4){ref-type="sec"}. Bars in all of the graphs represent mean values, with error bars showing SDs. Statistical significance (p \< 0.005) was determined through the Student's t test.

To confirm the above results, we performed saturation-binding experiments, in which a fixed amount of each PGRP was individually mixed with increasing amounts of either PG to reach saturation binding (i.e., no increase in the PGRP protein precipitating with PG). Contrary to previous results ([@bib4]), PGRP-SA in HemoBuffer did not display a significant preference between DAP-type (2.3 × 10^4^ a.u. at saturation) and Lys-type PG (2.7 × 10^4^ a.u. at saturation) ([Figure S5](#mmc1){ref-type="supplementary-material"}B). This was confirmed by measuring the K~D~ and B~max~ of PGRP-SA binding of Lys-type and DAP-type PG ([Table S2](#mmc1){ref-type="supplementary-material"}). The K~D~ for Lys-type PG binding of PGRP-SA was 182.4, whereas for DAP-type PG it was 88.94 (see [Table S2](#mmc1){ref-type="supplementary-material"}; of note, the lower the K~D~, the stronger the association).

In contrast, PGRP-LC showed a preference for DAP-type PG ([Figure S5](#mmc1){ref-type="supplementary-material"}C; 4 × 10^4^ a.u. at saturation) over Lys-type PG ([Figure S5](#mmc1){ref-type="supplementary-material"}C; 2 × 10^4^ a.u. at saturation) and bound significantly more DAP-type PG than PGRP-SA (compare curves for DAP-type PG in [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). However, the difference between binding of PGRP-SA and PGRP-LC to Lys-type PG was much less pronounced (2.7 × 10^4^ a.u. for PGRP-SA and 2 × 10^4^ a.u. for PGRP-LC; compare curves for Lys-PG in [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). This was corroborated by comparable B~max~ measurements (27,054 for PGRP-SA and 22,152 for PGRP-LC), indicating comparable numbers of PG-associated receptors in the PGRP-PG pellet at saturation. However, the K~D~s were different, indicating tighter binding of PGRP-SA to Lys-PG ([Table S2](#mmc1){ref-type="supplementary-material"}).

Contrary to previous results, our data above show that PGRP-SA binds similarly to both types of PG. PGRP-LC prefers DAP-type PG but does bind to Lys-type PG, and at saturation, the numbers of LC receptors recovered in the reaction to Lys-type PG were comparable to PGRP-SA, which is considered the bona fide receptor of Gram-positive bacteria.

Structural Evidence Indicates Binding of PGRP-SA and PGRP-LC to Both Types of PG {#sec2.3}
--------------------------------------------------------------------------------

Next, we wanted to investigate whether there is also structural evidence for the binding of PGRP-LC to Lys-type PG and whether the structure of PGRP-SA would allow binding to both Lys-type and DAP-type PG. Superposition of the two structures ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6F) and examination of their electrostatic potential ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C) indicated several relevant features: the electrostatic potential at the surface of PGRP-LC ([Figure S6](#mmc1){ref-type="supplementary-material"}A) calculated in the absence of PG would indicate a number of localized positively charged areas mainly associated with Lys423 and Arg349 ([@bib5]). Arg427 is the third proposed surface residue to complete the Lys-type PG exclusion ring. However, its potential is tempered by a hydrogen bond formed with the backbone of residue 353. It is notable that both Lys423 and Arg349 are located on the surface of the molecule and do not form any H-bonds with neighboring residues. They should therefore be relatively free in solution to present as any of a number of rotameric variants. This in turn could lead to the relocation of any positive potential further away from the binding site or its neutralization via interactions with negatively charged residues on the molecular surface. This would suggest that Lys-PG binding is probable in solution at measurable rates. In turn, this is something corroborated by our binding assays. Nevertheless, based on this structure ([@bib5]), the defining characteristic of the PGRP-LC binding groove is the conformation of Arg413, which securely anchors DAP-type PG and is likely to impose a preference for the latter via increased conformational stability ([Figure S6](#mmc1){ref-type="supplementary-material"}D). This is also corroborated by our results from the binding of PGRP-LC to quantified PG (see [Figures 4](#fig4){ref-type="fig"}, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B; [Table S2](#mmc1){ref-type="supplementary-material"}).

In the case of PGRP-SA, the structure (based on [@bib28]) is far more electronegative in the vicinity of the binding site ([Figure S6](#mmc1){ref-type="supplementary-material"}B), and the positive sites are compromised by a lack of positively charged residues; here, R349 is replaced by a glycine (G27), Lys423 is a tyrosine (Y100), and Arg427 is now an alanine (A104). Moreover, the replacement of the anchoring arginine in PGRP-LC with threonine in PGRP-SA ([Figure S6](#mmc1){ref-type="supplementary-material"}D) not only removes the two hydrogen bonds that would have stabilized DAP-PG but also leaves an accommodating void that can flexibly bind via a water molecule network to either type of PG ([Figures S6](#mmc1){ref-type="supplementary-material"}E and S6F). In this case, there should be little difference in binding affinity. Although more structures need to be generated to confirm this, the prediction is that PGRP-SA will be more equal in the binding of the different types of PGs than PGRP-LC. Our PG binding experiments ([Figure 4](#fig4){ref-type="fig"}) and saturation experiments ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B; [Table S2](#mmc1){ref-type="supplementary-material"}) showed that in the HemoBuffer, binding of PGRP-SA to DAP or Lys-type PG was statistically indistinguishable.

Flies Deficient for Both PGRP-SA and PGRP-LC Are More Susceptible to WTA-less Bacteria Than Flies Lacking Any One of These PGRPs {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------------

In broad terms, the working hypothesis in the field is that flies that are deficient for PGRP-SA are more susceptible to Gram-positive bacteria, while PGRP-LC mutants succumb to Gram-negative bacteria and Gram-positive bacilli ([@bib18]). We wanted to test this hypothesis comparing WTA-less bacteria with their parental strains. Estimated survival curves were analyzed using both the log rank (Mantel-Cox, see [Table S3](#mmc1){ref-type="supplementary-material"}) and the Gehan-Breslow-Wilcoxon test (see [Table S4](#mmc1){ref-type="supplementary-material"}) to determine statistical significance between the survival probabilities. The main difference between the tests is that the Gehan-Breslow-Wilcoxon method gives more weight to deaths at early time points, which correlates with the fact that *S. aureus* kills flies fast ([@bib2]). In contrast, the Mantel-Cox test gives equal weight to all time points.

Infection with *S. aureus* NCTC did confirm that *PGRP-SA*^*seml*^ homozygous mutant flies were significantly more susceptible than *PGRP-LC*^*ΔE12*^ homozygous mutant flies to wild-type *S. aureus* ([Figure 5](#fig5){ref-type="fig"}A). Nevertheless, the survival probability of homozygous double *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^ mutant flies was statistically distinct from (and reduced compared to) *PGRP-SA*^*seml*^ mutant flies, suggesting that PGRP-LC did contribute to the final sum of host survival following *S. aureus* infection ([Figure 5](#fig5){ref-type="fig"}A; see [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"} for statistics). This contribution became more evident when host survival following *S. aureusΔTagO* was considered. Specifically, when comparing *PGRP-SA*^*seml*^ to *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^, the differences in survival probabilities were more distinct compared to wild-type *S. aureus* infection, and this was reflected in the greater statistically significant difference in susceptibility ([Figure 5](#fig5){ref-type="fig"}B; compare *PGRP-SA*^*seml*^ to *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^ in *S. aureus* and *S. aureusΔTagO* in [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). This indicated that the role of PGRP-LC was more prominent in *S. aureusΔTagO* infection.Figure 5Survival Probability Patterns of Flies Deficient in PGRP-SA or PGRP-LC (or Both) following Infection with WTA-less Bacteria(A) Following infection with *S. aureus*, there was a statistically significant difference in the contribution of survival to infection when comparing either *PGRP-SA*^*seml*^ or *PGRP-LC*^*ΔE12*^ single mutants with the wild-type control *w*^*1118*^ (which survived more often) or with the homozygous *PGRP-SA*^*seml*^*; PGRP-LC*^*ΔE12*^ double mutant (which survived less often). However, PGRP-SA contributed more since *PGRP-SA*^*seml*^ was statistically closer to the double mutant.(B) Infection with *S. aureusΔTagO* increased the statistical difference between PGRP-SA and *PGRP-SA*^*seml*^*; PGRP-LC*^*ΔE12*^. This indicated the augmented participation of PGRP-LC in survival.(C) After infection with *B. subtilis*, the survival probabilities of flies followed a pattern in which both PGRPs participated and the double homozygote mutant displayed the highest susceptibility, while *w*^*1118*^ displayed the lowest susceptibility.(D) Nevertheless, removal of WTAs rendered both single mutants resistant to *B. subtilisΔTagO* as *w*^*1118*^ and the double heterozygote, whereas only the double homozygous mutant displayed a moderate susceptibility to infection.The results shown here are from pooled survival data (n = 87--100 for each genotype) from three independent sets of injections (there were no significant departures between repeats; p \> 0.1, log rank test) and plotted estimates of survival probabilities. To extract p values, populations were compared using log rank and Wilcoxon tests.See also the statistics in [Table S3](#mmc1){ref-type="supplementary-material"}.

Infection by *B. subtilis* showed that both PGRP-SA and PGRP-LC contributed to survival, albeit with significant statistical differences. However, the double mutant was significantly more susceptible than either of the single mutants ([Figure 5](#fig5){ref-type="fig"}C; [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). Following infection with *B. subtilisΔTagO*, the survival of both of the single mutants was statistically indistinguishable from the heterozygous double mutant and wild-type *w*^*1118*^ control exhibiting robust resistance to infection ([Figure 5](#fig5){ref-type="fig"}D; [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). In contrast, the double *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^ homozygous mutant was statistically distinct and succumbed more easily to infection than either single mutant ([Figure 5](#fig5){ref-type="fig"}D; [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). Of note, when injected with a sterile saline buffer (as a control for the injection itself), the survival of none of the PGRP mutants was different from the control (data not shown). In the host survival experiments described above, we used as controls the genetic background of the double mutant *w*^*1118*^ and the heterozygous siblings of the homozygous PGRP mutants. In all of the infections, the survival probabilities of the *w*^*1118*^ strain were the highest of all fly stocks challenged, the double mutant the lowest, and the double heterozygote in the center of the two ([Figure S7](#mmc1){ref-type="supplementary-material"}).

Growth of WTA-less Bacteria Inside the Host Depends on Both PGRPs {#sec2.5}
-----------------------------------------------------------------

To correlate fly survival with bacterial growth inside the host, survival results were combined with the measurements of pathogen growth in colony-forming units (CFUs). Our results are shown in [Figure 6](#fig6){ref-type="fig"}. The growth of both *ΔTagO* mutants was restricted in *w*^*1118*^ controls, in contrast to their parental strains (compare [Figure 6](#fig6){ref-type="fig"}A *S. aureus* and [Figure 6](#fig6){ref-type="fig"}B for *S. aureusΔTagO*; [Figure 6](#fig6){ref-type="fig"}C for *B. subtilis* and [Figure 6](#fig6){ref-type="fig"}D for *B. subtilisΔTagO*). The picture was different in PGRP mutants, in which growth of both parental bacterial strains ([Figures 6](#fig6){ref-type="fig"}A and 6B) and *ΔTagO* mutants increased through time ([Figures 6](#fig6){ref-type="fig"}B and 6D). However, the growth of *S. aureus* showed no difference between *PGRP-SA*^*seml*^ and *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^ double mutants until 36 h post-infection, indicating that PGRP-SA was the main restricting factor for wild-type *S. aureus*, and loss of PGRP-LC only added to the phenotype at later stages of infection ([Figure 6](#fig6){ref-type="fig"}A). Of note, *S. aureus* is a "fast killer," in which 40% of flies die in 72 h, with only 300 cells initial infection ([@bib2]).Figure 6Growth of WTA-less *S. aureus* and *B. subtilis* Inside the Host Depend on Both PGRPs, in Contrast to Wild-Type Bacteria(A) The growth of wild-type *S. aureus* was statistically indistinguishable between *PGRP-SA*^*seml*^ and *PGRP-SA*^*seml*^*; PGRP-LC*^*ΔE12*^ flies, except in the later stage of infection (36 h).(B) *S. aureusΔTagO* in wild-type flies showed a significant difference in the dynamics of pathogen clearance compared to *S. aureus* wild type, with the *ΔTagO* mutant being cleared rather than restricted. However, *S. aureusΔTagO* was able to grow significantly more in *PGRP-SA*^*seml*^*; PGRP-LC*^*ΔE12*^ than in *PGRP-SA*^*seml*^ flies at 24 and 36 h, showing a dependence on both PGRPs.(C) Growth of wild-type *B. subtilis* was dependent on PGRP-LC only, since bacterial growth in *PGRP-LC*^*ΔE12*^ versus *PGRP-SA*^*seml*^*; PGRP-LC*^*ΔE12*^ was statistically indistinguishable.(D) *B. subtilisΔTagO* grew better in *PGRP-SA*^*seml*^*; PGRP-LC*^*ΔE12*^ than in single *PGRP-LC*^*ΔE12*^ mutant flies, indicating that both receptors participated in restricting growth when WTA was removed.CFU comparisons were determined by Student's t test, in which ^∗^p \< 0.05 and ^∗∗∗∗^p \< 0.0001 indicate significance value. ns, non-significant.

However, *S. aureusΔTagO* growth showed increasing statistically significant differences between *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^ and *PGRP-SA*^*seml*^ mutants from 24 to 36 h post-infection ([Figure 6](#fig6){ref-type="fig"}B). This meant that when accessibility to cell wall PG was increased, both PGRPs were involved in restricting *S. aureus* at an earlier point in the infection.

The growth of *B. subtilis* was statistically indistinguishable between *PGRP-LC*^*ΔE12*^ and *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^ double mutants ([Figure 6](#fig6){ref-type="fig"}C). This was in contrast to *B. subtilisΔTagO* infection, in which there was a statistically significant increase in bacterial load in *PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^ double mutants compared to *PGRP-LC*^*ΔE12*^ at both 24 and 36 h post-infection ([Figure 6](#fig6){ref-type="fig"}D). This indicated that when WTAs were removed from *B. subtilis*, not only PGRP-LC but also PGRP-SA started to play a role in restricting pathogen growth. Therefore, our CFU measurements indicated that both PGRPs were involved in the restriction of WTA-less bacteria, in contrast to the wild-type parental bacterial strains.

Infection with WTA-less Bacteria Abolishes Differential Antimicrobial Peptide Gene Expression {#sec2.6}
---------------------------------------------------------------------------------------------

To trace signaling activation over time downstream of the two PGRPs following infection and ascertain whether the bindings we have observed led to the induction of immune activity, we measured AMP gene expression. As proxy for the PGRP-SA/Toll signaling pathway, we used the AMP gene *drosomycin* (*drs*), whereas as a proxy for PGRP-LC/IMD signaling pathway activity, we measured the induction of the AMP gene *diptericin* (*dipt*).

Infection of *w*^*1118*^ flies with *B. subtilis* induced a robust differential activation of antimicrobial peptide gene expression with almost 100× more *dipt* than *drs* at 48 h ([Figure 7](#fig7){ref-type="fig"}A; [Figure S8](#mmc1){ref-type="supplementary-material"}A, AMP levels normalized with CFUs). In contrast, infection with *B. subtilisΔTagO* did not induce a differential response, indicating a more equal participation of the two PGRPs in inducing downstream signaling ([Figures 7](#fig7){ref-type="fig"}B and [S8](#mmc1){ref-type="supplementary-material"}B). Infection with *S. aureus* triggered a robust *dipt* induction, which was 2× more than *drs*, contrary to expectations for an Lys-type PG bacterium ([Figures 7](#fig7){ref-type="fig"}C and [S8](#mmc1){ref-type="supplementary-material"}C) but in keeping with the recent literature in *Drosophila* ([@bib39]) and the Oriental fruit fly, *Bactrocera dorsalis* ([@bib32]). In contrast, infection with *S. aureusΔTagO* induced statistically indistinguishable AMP levels, showing that when WTAs were removed, both PGRPs participated equally in AMP induction ([Figure 7](#fig7){ref-type="fig"}D; [Figure S8](#mmc1){ref-type="supplementary-material"}D, AMP levels normalized with CFUs).Figure 7PGRP-SA- and PGRP-LC-Mediated Transcriptional Induction of AMPs Is Lower but More Equal after WTA-less Bacterial Infection(A) *B. subtilis* induced a robust *dipt* induction almost 100× more than *drs*.(B) In contrast, *B. subtilisΔTagO* activated a lower but more equal AMP response, with the only significant difference observed at 6 h.(C) *S. aureus* also induced a robust *dipt* activation 4--5× higher at 48 h compared to *drs*.(D) *S. aureusΔTagO* induced *dipt* and *drs* gene expression, which presented no statistical difference across the time points studied.(E--H) To ascertain that *dipt* was induced by PGRP-LC following Lys-type infection and *drs* by PGRP-SA following DAP-type infection, we challenged *PGRP-SA*^*seml*^ mutants with *B. subtilis* (E) and *B. subtilisΔTagO* (F) and verified that *drs* expression following DAP-type bacterial infection was dependent on PGRP-SA. Similarly, infecting *PGRP-LC*^*ΔE12*^ with *S. aureus* (G) or *S. aureusΔTagO* (H) verified that the robust induction of *dipt* recorded was dependent on PGRP-LC.

To ascertain that *drs* was indeed under PGRP-SA control and *dipt* under PGRP-LC control, we used the relevant fly mutants. In this context, *PGRP-SA*^*seml*^ mutants failed to induce *drs* following infection with both *B. subtilis* ([Figure 7](#fig7){ref-type="fig"}E) and *B. subtilisΔTagO* ([Figure 7](#fig7){ref-type="fig"}F) while *PGRP-LC*^*ΔE12*^ flies did not induce *dipt* following both *S. aureus* ([Figure 7](#fig7){ref-type="fig"}G) and *S. aureusΔTagO* infection ([Figure 7](#fig7){ref-type="fig"}H).

These results showed that there was robust PGRP-LC-dependent *dipt* induction following *S. aureus* and *S. aureusTagO,* while there was also PGRP-SA-dependent induction of *drs* transcription following *B. subtilisTagO* challenge.

However, wild-type flies displayed lower AMP level induction after challenge with either *ΔTagO* mutant. The lower level of activation of the *ΔTagO* mutants was due to the higher rate of phagocytosis, which was taking these bacteria from circulation early (as supported by CFUs in [Figure 6](#fig6){ref-type="fig"}; see also [Video S2](#mmc3){ref-type="supplementary-material"}).

Video S2. *Ex Vivo* Interaction between Primary Larval Macrophages Expressing Moesin-GFP with Bacteria, Related to Figure 7*S. aureus* (up to 1mins:11secs), *S. aureusΔTagO* (1mins:12secs-2mins:13secs), *B. subtilis* (2mins:14secs-3mins:23secs), *B. subtilisΔTagO* (3mins:14secs-4mins:34secs), Schneider medium control (4mins:35secs-5mins:44secs) and heat killed *S. aureus* (5mins:45secs-6mins:56secs).

[Video S2](#mmc3){ref-type="supplementary-material"} represents live imaging of *ex vivo* phagocytosis by moesin-GFP-labeled primary larval hemocytes. When infected with *S. aureus*, hemocytes started exhibiting the hallmarks of cell death (shrinking and karyorrhexis; see [@bib41], [@bib38]) at ∼1:15 h post-infection ([Video S2](#mmc3){ref-type="supplementary-material"}, up to 1 min:11 s). In contrast, infection with *S. aureusΔTagO* induced death at ∼4:30 h, thus making more cells available for a longer time to engage in phagocytosis and pathogen clearance ([Video S2](#mmc3){ref-type="supplementary-material"}, 1 min:12 s---2 min:13 s). *B. subtilis* induced the hallmarks of death much later as compared to *S. aureus* (at ∼12:30 h post-infection) ([Video S2](#mmc3){ref-type="supplementary-material"}, 2 min:14 s--3 min:23 s). However, *B. subtilis ΔTagO* infection did not induce cellular death at all and was cleared ([Video S2](#mmc3){ref-type="supplementary-material"}, 3 min:24 s--4 min:34 s), indicating again differences between parental strain and WTA-less bacteria. The outcome of infection with *B. subtilis ΔTagO* infection was similar to hemocyte primary culture without infection, in which cells were able to survive an 18-h observation period *ex vivo* in Schneider's medium ([Video S2](#mmc3){ref-type="supplementary-material"}, 4 min:35 s--5 min:44 s). Similarly, infection with heat-killed *S. aureus* did not induce hemocyte death, and host macrophages were able to contain the infection ([Video S2](#mmc3){ref-type="supplementary-material"}, 5 min:45 s--6 min:56 s). Our working hypothesis is that prolonged survival of hemocytes in infections with WTA-less bacteria would increase bacterial uptake by macrophages, which are the first line of defense. These would leave much less bacteria to activate AMP responses that are typically induced much later during the timeline of the response to infection ([@bib33]). Thus, AMP levels were lower in WTA-less infection.

Nevertheless, bacteria in WTA-less infections triggered per CFU equally PGRP-SA-dependent *drs* and PGRP-LC-dependent *dipt*, in contrast to the parental bacterial strains that activated per CFU differential AMP transcription.

Discussion {#sec3}
==========

In *Drosophila,* the generally accepted explanation for selective activation of immune pathways at the recognition level has been that PGRPs structurally discriminate between different types of PGs. This discrimination occurs on the basis of the amino acid present at position 3 of the stem peptide. Thus, PGRP-SA recognizes Lys (found in Gram-positive bacteria), while PGRP-LC interacts with DAP (found in Gram-negative bacteria and Gram-positive bacilli). The idea of structural discrimination at the level of the stem peptide resulted from a combination of observations, including PG binding assays, structural work, and *in vivo* infection experiments. However, there are several concerns with the experiments that support this Lys/DAP dichotomy or with the interpretation of the data. A summary of these follows.

First, the PG binding experiments were conducted with a buffer that is often used to solubilize proteins, but that was very different from hemolymph (where interactions between PG and PGRPs take place).

Second, the PG used for binding as well as infection experiments was quantified only by weight and not by the number of disaccharide GlcNAc-MurNAC added to the binding reaction.

Third, the structural data available and previously described referred to the binding of monomeric PG, whereas PGRP-SA and PGRP-LCx are both able to bind polymeric PG and may do so *in vivo*. In the context of polymeric PG binding, the small difference of a carboxyl group on the Cε with [d]{.smallcaps}-chirality in DAP may not be as important for downstream signaling. Moreover, superposition of the two structures showed that the electrostatic potential at the surface of both PGRPs suggests that binding to both types of PG in solution is probable.

Based on the published structure ([@bib5]), the defining characteristic of the binding groove is the conformation of Arg413, which securely anchors DAP-type PG and is likely to impose a preference for the latter via increased conformational stability ([Figure S6](#mmc1){ref-type="supplementary-material"}D). This preference was verified with quantitative binding to Lys and DAP-type PG, in which the latter was bound in increased quantities by PGRP-LC ([Figure S6](#mmc1){ref-type="supplementary-material"}C; [Table S2](#mmc1){ref-type="supplementary-material"}). Nevertheless, PGRP-LC did bind Lys-type PG *in vitro*. Moreover, binding of PGRP-LC to Lys-type bacteria was recorded *ex vivo*, and this binding resulted in a robust AMP induction that was statistically higher than the one elicited through PGRP-SA, considered the bona fide receptor for Gram-positive bacteria ([Figure 7](#fig7){ref-type="fig"}C). This indicated that the upstream binding preferences of PGRP-LC did not result in differences in transcriptional AMP induction.

For PGRP-SA, replacement of the anchoring Arg413 from PGRP-LC with a threonine should leave an accommodating void that can flexibly bind via a water molecule network either types of PG ([Figure S6](#mmc1){ref-type="supplementary-material"}F). In this case, there should be no noticeable difference in binding affinity. We found little difference between PGRP-SA binding to Lys PG compared with DAP-type PG ([Figures 4](#fig4){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}).

Our results showed that when WTAs were removed, the binding of PGRPs to whole bacteria was significantly improved. This, however, was not reflected in binding assays to purified PG, showing that the increase in binding was about accessibility to PG on the bacterial cell wall, not about changing the WTA-less PG itself. This is consistent with the fact that purified PG from WTA-less bacteria and their parental strains had no significant differences in their HPLC profile analysis that could lead to an improved binding of PGRP-SA or PGRP-LC ([@bib1]).

The above results show that when WTAs were removed from bacteria, the majority of the observed phenotype attributed to selective recognition and downstream signaling based on the bacterial type were either abolished or diminished. This was accompanied by PGRP binding to whole bacteria, irrespective of PG type, in which both PGRPs played a role in host survival and restricting pathogen growth. Our results are in conflict with the general consensus of Lys/DAP discrimination and put forward an alternative explanation for differential immune triggering. We propose that at least for bacteria that have their PGs exposed to the host environment (Gram-positive bacteria and bacilli), accessibility to PG is a major factor restricting binding, recognition, and downstream signaling. Structural discrimination may still be important when monomeric PG fragments are the only means of "accessing" PG (in Gram-negative bacteria).

A fundamental issue when considering pathogen recognition in innate immunity is how a small number of germline coded receptors sense the vast variability of bacterial pathogens. Adapting receptors to an evolutionary conserved bacterial molecule essential for bacterial survival but not present in the host (e.g., PG), has been considered a productive host strategy. However, we believe that it would have been detrimental for the host to further specialize its non-enzymatic PGRP receptors to PG-stem peptide variants, as this would essentially decrease even more the effective number of possible productive host-pathogen recognition interactions, especially in an animal such as *Drosophila,* challenged by a wide variety of pathogens, each of which interacts rarely with it ([@bib15]). Put it another way, *Drosophila* is not subject to the arms race-type tight co-evolution with its pathogens that *Anopheles* is, for example, but it is subject to diffuse co-evolution with an array of non-specialist pathogens ([@bib14], [@bib15]).

Evolutionary studies on *Drosophila* PGRPs (including SA and LC) have shown that there is no strong co-evolution interaction, and as such, no need for specialization ([@bib15]). We propose that it was the accessibility to PGs on different bacterial cell wall structures that defined how PGRPs were able to bind to PG on whole bacteria and the specified differences in downstream signaling responses, instead of direct structural specialization, as previous studies suggested. Our results indicate that even when structural preference exists (as in the case of PGRP-LC), differences in downstream signaling are equalized when accessibility to PG on the cell wall is increased. More work is needed to test whether accessibility is also critical for PGRP-mediated recognition of whole bacteria in mammals.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial Strains***E. coli* DH5αInvitrogenCat No.11319019*E. coli* BL21 (DE3)InvitrogenCat No.C600003*B. subtilis*[@bib8]EB6*B. subtilis*Δ*tagO*[@bib8]EB1451*S. aureus*From R. NovickNCTC8325-4*S. aureus*Δ*tagO*[@bib2]NCTC8325-4 *tagO* null**Chemicals, Peptides, and Recombinant Proteins**Hemolymph-like buffer (HemoBuffer)This studyN/AFetal Calf SerumSigmaCat. No F2442Schneider's mediumGIBCOCat No. 21720024HClSigmaCat No. 7647-01-0RibitolChem SceneCat No. 488-81-3GlycerolSigmaCat No. 56-81-5MannosamineSigmaCat No. M4670**Critical Commercial Assays**Maxima First Strand cDNA synthesis kitThermo ScientificCat No. K1651SensiFASAT SYBR No-ROX kitBiolineCat No. BIO-98005Total RNA Purification Plus kitNorgen BiotekCat No. 48200Wizard PCR Clean Up kitPromegaCat No. A9281**Experimental Models: Organisms/Strains***PGRP-SA*^*seml*^[@bib24]N/A*PGRP-LC*^*ΔE12*^[@bib12]N/A*PGRP-SA*^*seml*^; *PGRP-LC*^*ΔE12*^This studyN/A*w; UAS-GFP::PGRP-LCx*[@bib31]Lemaitre Lab*Moesin-GFP*[@bib10]N/A*w\[1118\]; P{w\[+mC\] = Hml-GAL4.Delta}2*[@bib34]Stock No. 30139*TI{w\[+mW.hs\] = TI}Pis\[1\]/FM7a;P{w\[+mC\] = hs-Pis.MYC}3/TM2*Bloomington Stock CentreStock No. 27336**Oligonucleotides**PGRP-LCx cloning from IP15793 to pET21α: GGGAAGG\
GAATTCAACCAAACGGACTTGGATG" (forward)This studyN/APGRP-LCx cloning from IP15793 to pET21α: TGCGG\
CCGCAAGCTTTTAGTGATGGTGATGGTGATGGA\
TTTCGTGTGACCAGTGCG" (reverse)This studyN/Arp49 forward: AAGAAGCGCACCAAGCACTTCATCThis studyN/Arp49 reverse: TCTGTTGTCGATACCCTTGGGCTTThis studyN/Adiptericin forward: ACCGCAGTACCCACTCAATCThis studyN/Adiptericin reverse: GGTCCACACCTTCTGGTGACThis studyN/Adrosomycin forward: AGTACTTGTTCGCCCTCTTCGCTGThis studyN/Adrosomycin reverse: CCTTGTATCTTCCGGACAGGCAGTThis studyN/A**Recombinant DNA**PGRP-LCx isoform plasmidDGRCIP15793pET21αNovagen/MerckCat No 69740pET21α-m-Cherry-PGRP-LCxThis studyN/ApET21α-m-Cherry-PGRP-SA[@bib2]N/A**Software and Algorithms**ImageJNIH<https://imagej.en.softonic.com/>PyMol<https://pymol.org/2/><https://pymol.org/2/>GraphPad Prism 6GraphPad Software<https://www.graphpad.com/>SoftWoRxGE Healthcare<http://incelldownload.gehealthcare.com/bin/download_data/SoftWoRx/7.0.0/SoftWoRx.htm>**Other**Quantification of Peptidoglycan using HPAEC-PADThis studyN/A

Contact for Reagents and Resources Sharing {#sec4.2}
------------------------------------------

Further information and requests for resources reagents should be directed to and will be fulfilled by the Lead Contact, Petros Ligoxygakis (<petros.ligoxygakis@bioch.ox.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Bacterial strains and culture {#sec4.3.1}

*E. coli* strains DH5α and BL21(DE3) (both for construction and expression of the recombinant proteins), *B. subtilis* EB6 and EB6Δ*tagO* (EB1451) strains ([@bib8]) were grown either in Luria--Bertani broth (LB; Difco, France) or in Luria--Bertani agar (LA; Difco). *S. aureus* strains NCTC 8325-4 (reference strain, kind gift from R. Novick) and NCTC Δ *tagO* ([@bib2]) were grown either in Tryptic Soy broth (TSB; Difco) or in Tryptic Soy agar (TSA; Difco). All cultures were grown at 30°C with aeration, except when infected flies were crushed and plated for CFUs, the LA and TSA plates were incubated at 25°C.

### Fly Strains {#sec4.3.2}

All flies, stocks and crosses, were grown on standard cornmeal-agar medium at 25°C. We used PGRP-SA^*seml*^ ([@bib24]), *PGRP-LC*^*ΔE12*^ ([@bib12]), balancer stock Bl\#27336 flies (FBst0027336 from Bloomington *Drosophila* Stock Centre), *w*; UAS-GFP::PGRP-LCx ([@bib31]), Moesin-GFP ([@bib10]) and Hml^Δ^Gal4 ([@bib34]).

Method Details {#sec4.4}
--------------

### Plasmids {#sec4.4.1}

Plasmid IP15793 (*Drosophila* Genomics Resource Centre) containing the PGRP-LCx isoform, was used to amplify the PGRP domain (region 966 bp to1500 bp of the CDS) with the pair of primers (sequences from 5\` to 3\`): "GGGAAGGGAATTCAACCAAACGGACTTGGATG" (forward) and

"TGCGGCCGCAAGCTTTTAGTGATGGTGATGGTGATGGATTTCGTGTGACCAGTGCG" (reverse). Subsequently, the fragment was cloned into the EcoRI and EagI restriction sites of the pET21a backbones of the mCherry_PGRP-SA and rPGRP-SA vectors ([@bib2]). A 6x His-tag was added to the last coding triplet, before the stop codon, similar to the PGRP-SA constructs.

### PGRP-SA^seml^; PGRP-LC^ΔE12^ double mutant {#sec4.4.2}

For construction of the double mutant PGRP-SA^*seml*^; PGRP-LC^Δ*E12*^ I and III chromosome of *semmelweis* flies and *PGRP-LC*^*ΔE12*^ flies were balanced through cross with. For each F1 of these two independent crosses, flies with both balancers were selected and the cross between female virgins *seml*/*FM7* and *TM2*/+ with males *FM7*/y and *TM2*/*PGRP-LC*^*ΔE12*^ was set. Of this progeny, we selected female virgin flies that phenotypically presented both balancers and male flies that were not FM7 (hence were *seml* genotype) but presented TM2 phenotype.

Several single crosses between such females and males were set. After confirming the existence and viability of 1^st^ instar larvae, the parents were removed and checked for both the *seml* mutation as well as for *PGRP-LC*^*ΔE12*^. Briefly, gDNA was extracted and the *PGRP-LC*^*ΔE12*^ was amplified by PCR using the primers **"**CACACGCTGCCATATCAGAC" and "TATCGGTTTTCCTGGGTGAG**"** ([@bib25]). The corresponding PCR *PGRP-LC*^*ΔE12*^ fragment should show a 212 bp band. Only the single crosses of which both female and male showed such amplification were kept and these PCR products along with the PCR products using the forward primer **"**TTAGATCTTAGCACATCAACATC" and reverse primer "GACTACTGCAATTACTTGTAGTTG" (sequences from 5\` to 3\`) for amplification of the *semmelweis/PGRP-SA* gene were sent to sequencing to confirm the genotypes. Females and males that did not present balancers, i.e., homozygous for both *semmelweis* and *PGRP-LC*^*ΔE12*^ genes were collected. Finally, single crosses between one of these females and one male were set to obtain a homogeneous population of homozygous flies for *seml* and *PGRP-LC*^*ΔE12*^. Three different lines from three different single crosses were obtained, of which both the parents and progeny genotype was confirmed by PCR and sequencing. Results obtained from survival and CFU studies were similar for all lines tested. For construction of the single mutants, the respective mutant flies balanced with the Bl\#27336 flies were used and a similar approach as for the double mutant was followed. Again, three stocks for each single mutant, with one female and one male as progenitor parents for the whole stock were established. This was to ensure the *PGRP-SA*^*seml*^, *PGRP-LC*^*ΔE12*^ and the double mutant, were in a similar genetic background. Results obtained from survival and CFU studies were similar for all lines tested.

### Hemolymph-like buffer {#sec4.4.3}

This buffer (referred to in the text as HemoBuffer) was prepared according to previous studies ([@bib7]; [@bib37], see below on how HemoBuffer compares with these two publications). The suggested salts to prepare for the HemoBuffer are as follows (final concentration): Na~2~SO~4~.10H~2~O (7.3mM), NaH~2~PO~4~.H~2~O (34mM), Na~2~HPO~4~.7H~2~O (5mM), CaCl~2~.2H~2~O^∗^ (2mM), MgCl~2~.6H~2~O^∗^ (14.4mM), KCl (25mM). Please note that the final solution has a short shelf-life before precipitation occurs. We found that the easiest way to prepare this solution was to use the salt concentrations as above to prepare the final HemoBuffer solution. Furthermore, we found that CaCl~2~.2H~2~O and MgCl~2~.6H~2~O salts precipitate the solution if added together with the rest of the salts. Therefore, we found it useful to prepare a 10x concentration Stock Solution of HemoBuffer without CaCl~2~.2H~2~O and MgCl~2~.6H~2~O and prepare a fresh HemoBuffer solution by dilution and adding the CaCl~2~.2H~2~O and MgCl~2~.6H~2~O to the desired concentration.Ion/ Concentration (mM)[@bib7][@bib37]HemoBuffer pH 6.0K^+^**252425**Na^+^**1068758.6**Mg^2+^**14,42614.4**Ca^2+^**7,210,62**Cl^-^**58-57.8**PO~4~^2-^**39-39**SO~4~^2-^**7,3-7.3**

### Purification of recombinant PGRP-SA and PGRP-LC proteins {#sec4.4.4}

Recombinant proteins PGRP-SA and PGRP-LC with and without the mCherry fluorescent tag were purified using a protocol adapted from [@bib2], [@bib3].

### Construction of mCherry_PGRP-SA mutant proteins {#sec4.4.5}

The mCherry_PGRP-SA vector ([@bib2]) was used as a template to perform the following mutations: C54Y, also known as the PGRP-SA^*seml*^ mutation ([@bib24]), and C48YC54Y. The positions denoted in the nomenclature refer to the position of the mutated amino acid residue in the primary sequence of the native protein that lacks the signal peptide. Mutants were constructed by Site-Directed Mutagenesis PCR with appropriate primers, followed by DpnI digestion at 37°C. Amplified PCR products were cleaned using Wizard PCR Clean Up kit (Promega) and transformed into DH5α competent cells. Following confirmation of the sequence present in the transformed plasmids, these were transformed into BL21a (DE3) *E. coli* strain, which was used as an expression system. Proteins were then purified as previously described ([@bib2]).

### Purification of Peptidoglycan {#sec4.4.6}

The cell walls and PGs of *S. aureus* and *B. subtilis* parental and mutant strains were purified and analyzed as reported previously ([@bib11]).

### Binding of PGRPs to whole bacteria and imaging {#sec4.4.7}

was performed as in [@bib2].

### Quantification of PG using HPAEC-PAD {#sec4.4.8}

Sugar components of the purified PGNs were analyzed using HPAEC-PAD (High Performance Anion Exchange Chromatography coupled with Pulsed Amperometric Detection). After quantification of the Glucosamine and Muramic acid in each PGN sample, the final PGN suspensions were adjusted to the same amount of Muramic acid for further studies.

### Hydrolysis of PG into its basic constituents and separation of the monosaccharides {#sec4.4.9}

Three repeats for each PGN sample and three different batches of quantification were performed because as PGN is insoluble in aqueous solution, these repeats minimize potential errors in the quantification. The pure PGN suspension was left O/N stirring at RT for maximum homogenization. 20 μL of the suspensions were hydrolysed in 3 M HCl at 95°C for 2 h (150 μL reaction volume). The hydrolysed suspension was lyophilized until it was completely dried and resuspended in 500 μL of MilliQ H~2~O and lyophilized O/N. Finally, the acid-free hydrolysed material was resuspended in 150 μL MilliQ H~2~O.

For monosaccharide separation 10 μL of the samples were injected in a Thermo Scientific Dionex ICS-5000 system, in 18 mM NaOH constant and a gradient of 1 M NaCH~3~COO and MilliQ H~2~O. The MilliQ H~2~O as all the eluents were in MilliQ H~2~O of resistivity ≥ 18 MΩ, filtered with 0.2 μm ϕ pore filter and degassed for 15 min in an ultrasonic bath. Between the eluents pump and the injection valve it was used a BorateTrap™ column to remove borate contamination from eluents. An AminoTrap™ (Thermo Scientific Dionex AminoTrap) was used as a pre-treatment column to remove the amino acids from the samples, thus only the sugars passed to the CarboPac PA10 column (Thermo Scientific CarboPac PA10) where they were separated. Each injection was done in triplicates.

### Control samples for PG purification {#sec4.4.10}

#### Controls for HCl-mediated PG hydrolysis {#sec4.4.10.1}

To assess if hydrolysis had been complete, it was injected non-HCl treated Glucosamine, Muramic acid, *N*-acetylglucosamine and *N*-acetylmuramic acid. If the hydrolysis was complete, only Glucosamine and Muramic acid should be detected because the *N*-acetyl groups were removed by the acid treatment. Also these same samples HCl treated were injected, to determine if the hydrolysis had not destroyed the sugar molecules. After HCl treatment, only Glucosamine and Muramic acid should be detected and the areas of the peaks should be similar to the areas of the non-hydrolysed Glucosamine and Muramic acid standards because, theoretically, it was injected the same concentration for all of them.

#### Controls to confirm the purity of the PG {#sec4.4.10.2}

Injection of 1 mM of Ribitol, Glycerol and Mannosamine (HCL and non-HCL treated) to determine whether the PGN was indeed pure or still had WTAs attached.

### Controls for quantification of Glucosamine and Muramic acid {#sec4.4.11}

Injection of fresh solutions of Glucosamine and Muramic acid, at different concentrations - 1 mM followed by 1/2 dilutions until 31.25 μM. The area of these peaks in the chromatogram were used to plot the calibration curve that if r^2^∼1, the equation was used for the quantification of Glucosamine and Muramic acid in each PGN sample. Since N-acetylglucosamine and N-acetylmuramic acid are converted into Glucosamine and Muramic acid, respectively, under this hydrolysis conditions, we can control if total sample hydrolysis has occurred. In a total hydrolysis scenario no N-acetylglucosamine and N-acetylmuramic acid should be detectable ([@bib6]).

### Quantification of Glucosamine and Muramic acid {#sec4.4.12}

The area of each peak corresponding to either Glucosamine or Muramic acid was quantified using the Thermo Scientific Dionex Chromeleon Chromatography Data (CDS) System software and thus the correspondent number of moles was calculated. PGN suspensions to be used in the co-precipitation assays were made in MilliQ H~2~O and they were diluted to the same number of moles of Muramic acid of the PGN that was more diluted.

### PG-PGRP co-precipitation assays {#sec4.4.13}

Co-precipitation or pull-down assays intended to determine the binding affinity of the PGRPs to both pure PG and to live cells, i.e., whole bacteria. The PG pull down assays are quantitative assays performed with the non-fluorescent tagged rPGRPs and analyzed by SDS-PAGE. Due to the non-solubility of the PGN in aqueous solutions, the amount of protein that binds is harvested with it. The bacterial binding assays are qualitative and were performed with the mCherry_PGRPs for microscopy visualization.

For the assays, PG suspensions at 2.89x10^−1^ nmol of Muramic acid/μL of PG were thoroughly mixed and 20 μL were taken and spun down for 3 min at RT, 16.1 x1000 *g*. The supernatants were carefully removed, in particular the NCTC Δ *tagO* who's PGN does not pellet well like the others and hence it is easily aspirated. To the pellets it was added 0.3 mg/mL final concentration of either PGRP-SA or PGRP-LC in a 200 μL reaction volume, filling up the volume with the reaction buffer (20 mM Tris-HCl pH 8.0; 300 mM NaCl or PBS 1X pH 6.0 or Hemo Buffer -- 7.3 mM Na~2~SO~4~.10H~2~O; 34 mM NaH~2~PO~4~.H~2~O; 5 mM Na~2~HPO~4~.7H~2~O; 25 mM KCl; 2 mM CaCl~2~; 14.4 mM MgCl~2~.6H~2~O; pH 6.0-6.2 adjusted with NaOH). The mixes were incubated at 25°C for 30 min, without shaking and then centrifuged for 5 min at RT 0.8 × 1000 *g*. The pellets were washed with 200 μL of reaction buffer and centrifuged for 5 min at RT, 3.2 x1000 *g*. The pellets were finally resuspended in 20 μL of 2X SDS LB and boiled for 5 min. The samples were centrifuged for 3 min at RT, 16.1 x1000 *g*. The supernatants were recovered (20 μL) into a fresh tube. This collection step allows the loading on the gel to be quick, clean and guarantees that only the supernatant and not bits of PG were loaded, which is important for comparing and quantifying the binding affinities. The full supernatant volume was loaded on a 12% SDS-PAGE gel. Resulting bands were visualized by Coomassie Blue Staining and both imaging and quantification were performed using a Gel Doc™ EZ Gel (Bio-Rad, USA). For quantification purposes of the bindings, each experiment was repeated in two different days, with two different batches of buffers (made fresh).

### Live bacteria co-precipitation assays {#sec4.4.14}

Bacteria were grown to OD~600nm~ ∼0.5 and 1 mL aliquot was centrifuged for 5 min at RT, 16.1 x1000 *g*. The cells were washed with 500 μL of HemoBuffer and centrifuged again. They were resuspended in 0.3 mg/mL final concentration of either mCherry_PGRP-SA or mCherry_PGRP-LC in a 200 μL reaction volume, filling up the volume with Hemo buffer and incubated at RT for 5 min without shaking. The "cells-bound PGRPs" complexes were harvested for 5 min at RT, 7.5 x1000 *g*. The pellets were washed twice with 200 μL of Buffer. Finally, the pellets were resuspended in the left-over volume of the washings and 2 μL was loaded on a 1.2% (w/v) Agarose-PBS slides (it does not dissolve in HemoBuffer). Images were acquired with a GE Healthcare DeltaVision Elite integrated imaging system, in the conventional mode at 25°C using an Olympus 150x 1.45 NA TIRF Objective (Olympus, USA) using the SoftWoRx software (GE Healthcare).

### Quantification of binding of fluorescent PGRPs to bacterial cells {#sec4.4.15}

This was performed in Image-J. Briefly, a threshold was applied to the phase image to obtain a mask that harbors the cells. Since PGRPs bind exogenously this mask was slightly dilated to encompass the fluorescence signal. The mask was processed by the watershed algorithm to separate the area of cells in close proximity and the resulting mask was used to create a list of Region of Interest (ROI), with each ROI harboring a different object. The list of ROIs was used to measure the fluorescent signal intensity after subtracting the background fluorescence. The average signal intensity of each ROI was used as a measure of the binding intensity.

### Survivals and CFUs {#sec4.4.16}

Bacterial cultures were grown overnight. Optical density was adjusted with the appropriate medium culture as follows: *B. subtilis* 5.0, *B. subtilis* Δ *tagO* 7.0, *S. aureus* 0.5 and *S. aureus* Δ *tagO* 0.7. 500μL of these cultures was centrifuged at RT for 10min, 3380 x *g*. The cells were washed once with 1mL of PBS (Phosphate-Saline Buffer) and resuspended in 500μL of PBS. 32.2 nL of bacterial suspension was injected in thorax of 3-5-day old flies using a nanoinjector (Nanoject II; Drummond Scientific, Broomall, PA). The infected flies were kept at 25°C and monitored for 72h every 12h. For determination of the CFUs, infected flies were collected at different time-points, homogenized and plated in the appropriate media and incubated at 25°C for 24h-48h. Survival curves and CFUs were determined for at least 3 independent experiments for each infection with (n = 30/infection).

### Measurements of gene expression in whole flies {#sec4.4.17}

Total RNA was extracted from whole flies (5 females) from three biological repeats upon injection using the Total RNA Purification Plus kit (Norgen Biotek), and cDNA was prepared from 0.5 mg total RNA using the Maxima First Strand cDNA synthesis kit (Thermo Scientific). The reaction conditions involved a step at 25°C for 10 min followed by a 15-minute step at 65°C and ending with a 5 min step at 85°C. QPCR reactions were carried out with the SensiFASAT SYBR No-ROX kit (Bioline) in a Corbet Rotor-Gene 6000 qPCR machine (QIAGEN) using 2 μl of cDNA template diluted tenfold and 400nM of each primer. Expression values were calculated using the DDCt method and normalized to rp49 expression levels. List of primers as follows:rp49 forward: AAGAAGCGCACCAAGCACTTCATCrp49 reverse: TCTGTTGTCGATACCCTTGGGCTTdiptericin forward: ACCGCAGTACCCACTCAATCdiptericin reverse: GGTCCACACCTTCTGGTGACdrosomycin forward: AGTACTTGTTCGCCCTCTTCGCTGdrosomycin reverse: CCTTGTATCTTCCGGACAGGCAGT

### Time-lapse microscopy {#sec4.4.18}

For microscopy of the GFP::PGRP-LCx binding to live bacterial cells, *w* UAS-GFP::PGRP-LCx virgin females were crossed with Hml^Δ^Gal4. Primary macrophages from F1 third instar larvae were used as described below. All other videos were done using primary macrophages from Moesin-GFP third instar larvae.

#### Macrophage preparation {#sec4.4.18.1}

Three third instar larvae were washed in 1 mL of ddH~2~O followed by 50% (v/v) bleaching and vortex. The larvae were quickly washed three times with autoclaved MilliQ H~2~O and left swimming while the slides were prepared. Into previously washed metal slides (100% (v/v) Ethanol) with a 1.0 mm coverslip it was put Schneider medium supplemented with 5% Fetal Calf Serum. The larvae were bled into the medium and the macrophages were let settle for 1 h at RT in a humid chamber.

#### Preparation of the bacteria {#sec4.4.18.2}

200 μL of an O/N culture were harvested at RT and washed with of Schneider. The cells were resuspended in 200 μL of Schneider with 0.5 μL of a DAPI solution (at 1 mg/mL in MilliQ H~2~O) and incubated for 5 min at RT, without shaking. The cells washed with 200 μL of Schneider and resuspended in 100 μL of Schneider. Finally, they were dilute 1/10 in Schneider in a 200 μL final volume.

#### Imaging of macrophages-bacteria interaction {#sec4.4.18.3}

To image the interactions between bacteria and macrophages, 200 μL of bacterial suspension was added on macrophages cultures in a "well slide" as previously described ([@bib27]). Briefly, well slides were prepared by gluing a coverslip with SYLGARD 184 Elastomer (Dow Corning) to an aluminum metal slide with a central hole of 1.5cm diameter. Approximately 200 μL of medoum was added to the well, macrophages isolated into this and allowed to settle onto the coverslip in a humidifier chamber. Before mounting on the microscope, an YSI 5775 Standard Membrane (YSI Incorporated, Japan) was placed over the medium to reduce dehydration and improve imaging. This was covered with a humidifier chamber for long-term imaging. Live imaging of UAS-GFP-PGRP-LCx haemocytes was performed at 25°C in a humid chamber for 12 h at 15 min intervals. With the same conditions, live imaging of moesin-GFP hemocytes was performed for 18h at 3min intervals. In all experiments we used a GE Healthcare DeltaVision Elite integrated imaging system and an Olympus MPLAPON-Oil immersion objective (100X 1.40 NA). For high-sensitivity imaging and to allow lower intensities of excitation light, we used the Photometrics Evolve back-thinned EMCCD camera. Time-lapse images were denoised post acquisition using an implementation of the Patch-Based Denoising algorithm ([@bib17]). Default parameters were used, except: number of iterations ( = 3), adaptability ( = 10) and patch radius ( = 3).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

All data was plotted and analyzed using GraphPad Prism 5 (GraphPad Software, Inc.). Statistical significance for CFU data was determined by Student's t test. To determine statistical significance between them, estimated survival probability curves were analyzed using the Log-rank (Mantel-Cox) and Wilcoxon tests.
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